Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy : Phase 2 study results
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved for the treatment of various solid tumors. In gastric cancer, genes commonly harbor mutations in the homologous recombination DNA repair pathway, potentially increasing sensitivity to PARPi. Pamiparib (BGB-290) is a small molecule inhibitor of PARP1 and PARP2.
METHODS: The PARALLEL-303 study (NCT03427814) investigated the efficacy and safety of pamiparib 60 mg orally (PO) twice daily (BID) versus placebo PO BID as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy. The primary endpoint of this double-blind, randomized, global phase 2 study was progression-free survival (PFS) (RECIST version 1.1; per investigator assessment). Secondary endpoints included overall survival (OS) and safety.
RESULTS: In total, 136 patients were randomized 1:1 to receive pamiparib (n = 71) or placebo (n = 65). Median PFS was numerically longer with pamiparib versus placebo but did not reach statistical significance (3.7 months [95% confidence interval (CI): 1.9, 5.3] vs. 2.1 months [95% CI: 1.9, 3.8]; hazard ratio 0.8 [95% CI: 0.5, 1.2]; p = 0.1428). Median OS was 10.2 months (95% CI: 8.7, 16.3) in the pamiparib arm versus 12.0 months (95% CI: 8.2, not estimable) in the placebo arm. Overall, 8 patients (11.3%) in the pamiparib arm and 2 patients (3.1%) in the placebo arm experienced ≥1 TEAE leading to treatment discontinuation.
CONCLUSIONS: Maintenance pamiparib did not meet statistical significance for superiority versus placebo for PFS, but was well tolerated with few treatment discontinuations; no unexpected safety signals were identified.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Cancer medicine - 12(2023), 12 vom: 13. Juni, Seite 13145-13154 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ciardiello, Fortunato [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 04.07.2023 Date Revised 05.07.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/cam4.5997 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM35762260X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM35762260X | ||
003 | DE-627 | ||
005 | 20231226073009.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/cam4.5997 |2 doi | |
028 | 5 | 2 | |a pubmed24n1192.xml |
035 | |a (DE-627)NLM35762260X | ||
035 | |a (NLM)37260158 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ciardiello, Fortunato |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy |b Phase 2 study results |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.07.2023 | ||
500 | |a Date Revised 05.07.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
520 | |a BACKGROUND: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved for the treatment of various solid tumors. In gastric cancer, genes commonly harbor mutations in the homologous recombination DNA repair pathway, potentially increasing sensitivity to PARPi. Pamiparib (BGB-290) is a small molecule inhibitor of PARP1 and PARP2 | ||
520 | |a METHODS: The PARALLEL-303 study (NCT03427814) investigated the efficacy and safety of pamiparib 60 mg orally (PO) twice daily (BID) versus placebo PO BID as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy. The primary endpoint of this double-blind, randomized, global phase 2 study was progression-free survival (PFS) (RECIST version 1.1; per investigator assessment). Secondary endpoints included overall survival (OS) and safety | ||
520 | |a RESULTS: In total, 136 patients were randomized 1:1 to receive pamiparib (n = 71) or placebo (n = 65). Median PFS was numerically longer with pamiparib versus placebo but did not reach statistical significance (3.7 months [95% confidence interval (CI): 1.9, 5.3] vs. 2.1 months [95% CI: 1.9, 3.8]; hazard ratio 0.8 [95% CI: 0.5, 1.2]; p = 0.1428). Median OS was 10.2 months (95% CI: 8.7, 16.3) in the pamiparib arm versus 12.0 months (95% CI: 8.2, not estimable) in the placebo arm. Overall, 8 patients (11.3%) in the pamiparib arm and 2 patients (3.1%) in the placebo arm experienced ≥1 TEAE leading to treatment discontinuation | ||
520 | |a CONCLUSIONS: Maintenance pamiparib did not meet statistical significance for superiority versus placebo for PFS, but was well tolerated with few treatment discontinuations; no unexpected safety signals were identified | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Clinical Trial, Phase II | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a clinical trial | |
650 | 4 | |a gastric cancer | |
650 | 4 | |a maintenance | |
650 | 4 | |a phase 2 | |
650 | 4 | |a poly(ADP-ribose) polymerase inhibitors | |
650 | 7 | |a pamiparib |2 NLM | |
650 | 7 | |a 8375F9S90C |2 NLM | |
650 | 7 | |a Platinum |2 NLM | |
650 | 7 | |a 49DFR088MY |2 NLM | |
650 | 7 | |a Fluorenes |2 NLM | |
700 | 1 | |a Bang, Yung-Jue |e verfasserin |4 aut | |
700 | 1 | |a Cervantes, Andrés |e verfasserin |4 aut | |
700 | 1 | |a Dvorkin, Mikhail |e verfasserin |4 aut | |
700 | 1 | |a Lopez, Charles D |e verfasserin |4 aut | |
700 | 1 | |a Metges, Jean-Philippe |e verfasserin |4 aut | |
700 | 1 | |a Sánchez Ruiz, Antonio |e verfasserin |4 aut | |
700 | 1 | |a Calvo, Mariona |e verfasserin |4 aut | |
700 | 1 | |a Strickland, Andrew H |e verfasserin |4 aut | |
700 | 1 | |a Kannourakis, George |e verfasserin |4 aut | |
700 | 1 | |a Muro, Kei |e verfasserin |4 aut | |
700 | 1 | |a Kawakami, Hisato |e verfasserin |4 aut | |
700 | 1 | |a Wei, Jia |e verfasserin |4 aut | |
700 | 1 | |a Borg, Christophe |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Zhaoyin |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Neal |e verfasserin |4 aut | |
700 | 1 | |a Pelham, Robert J |e verfasserin |4 aut | |
700 | 1 | |a Shen, Lin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 12(2023), 12 vom: 13. Juni, Seite 13145-13154 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2023 |g number:12 |g day:13 |g month:06 |g pages:13145-13154 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.5997 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2023 |e 12 |b 13 |c 06 |h 13145-13154 |